Dynavax Technologies Dirección
Dirección controles de criterios 3/4
El CEO de Dynavax Technologies' es Ryan Spencer , nombrado en Dec 2019, tiene una permanencia de 4.33 años. compensación anual total es $5.81M, compuesta por 13.1% salario y 86.9% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.18% de las acciones de la empresa, por valor de $2.62M. La antigüedad media del equipo directivo y de la junta directiva es de 3.3 años y 5.8 años, respectivamente.
Información clave
Ryan Spencer
Chief Executive Officer (CEO)
US$5.8m
Compensación total
| Porcentaje del salario del CEO | 13.1% |
| Permanencia del CEO | 4.4yrs |
| Participación del CEO | 0.2% |
| Permanencia media de la dirección | 3.3yrs |
| Promedio de permanencia en la Junta Directiva | 5.9yrs |
Actualizaciones recientes de la dirección
Recent updates
Dynavax: Holding Firm Despite Its Missing Cash Cow
Mar 23Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?
Mar 06
Dynavax Technologies Corporation's (NASDAQ:DVAX) Business And Shares Still Trailing The Industry
Jan 31These 4 Measures Indicate That Dynavax Technologies (NASDAQ:DVAX) Is Using Debt Safely
Aug 02Improved Earnings Required Before Dynavax Technologies Corporation (NASDAQ:DVAX) Shares Find Their Feet
Jun 02We Think Dynavax Technologies (NASDAQ:DVAX) Can Manage Its Debt With Ease
May 03Dynavax Technologies (NASDAQ:DVAX) Seems To Use Debt Rather Sparingly
Jan 16Clover, Dynavax COVID-19 vaccine gets EU GMP certificate
Sep 20Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?
Sep 12The Alphavaxers: Dynavax And Novavax, 2 Quarters On
Aug 22Dynavax up 8% after raising full-year guidance for key adjuvant product, Q2 beats
Aug 04Are Investors Undervaluing Dynavax Technologies Corporation (NASDAQ:DVAX) By 41%?
Jun 03Dynavax: Evolving Endemic Situation Adds To Its Risk
May 23Dynavax Technologies' (NASDAQ:DVAX) Performance Is Even Better Than Its Earnings Suggest
May 12Dynavax Technologies (NASDAQ:DVAX) Could Easily Take On More Debt
May 10Dynavax Technologies: Full Speed Ahead
Mar 01Here's Why Dynavax Technologies (NASDAQ:DVAX) Can Manage Its Debt Responsibly
Jan 28Dynavax: A Coronavirus Growth Story
Jan 17Is Dynavax Technologies Corporation (NASDAQ:DVAX) Expensive For A Reason? A Look At Its Intrinsic Value
Nov 18The Momentum Investor: Spotlight On Dynavax Technologies
Oct 25Dynavax And TLR Biology: Long-Delayed But Outstanding Success
Oct 16These 4 Measures Indicate That Dynavax Technologies (NASDAQ:DVAX) Is Using Debt Reasonably Well
Oct 02Upgrade: Analysts Just Made A Meaningful Increase To Their Dynavax Technologies Corporation (NASDAQ:DVAX) Forecasts
Aug 10Dynavax: Earnings This Year Ought To Surprise To The Upside
Aug 01Is Dynavax Technologies (NASDAQ:DVAX) Weighed On By Its Debt Load?
May 30Dynavax shares down 6% on launch of $200M debt offering
May 10Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Dec 31 2023 | US$6m | US$760k | -US$6m |
| Sep 30 2023 | n/a | n/a | US$61m |
| Jun 30 2023 | n/a | n/a | US$111m |
| Mar 31 2023 | n/a | n/a | US$236m |
| Dec 31 2022 | US$6m | US$695k | US$293m |
| Sep 30 2022 | n/a | n/a | US$320m |
| Jun 30 2022 | n/a | n/a | US$228m |
| Mar 31 2022 | n/a | n/a | US$104m |
| Dec 31 2021 | US$5m | US$600k | US$72m |
| Sep 30 2021 | n/a | n/a | -US$39m |
| Jun 30 2021 | n/a | n/a | -US$6m |
| Mar 31 2021 | n/a | n/a | -US$62m |
| Dec 31 2020 | US$2m | US$515k | -US$75m |
| Sep 30 2020 | n/a | n/a | -US$97m |
| Jun 30 2020 | n/a | n/a | -US$138m |
| Mar 31 2020 | n/a | n/a | -US$129m |
| Dec 31 2019 | US$3m | US$391k | -US$156m |
Compensación vs. Mercado: La compensación total ($USD5.81M) de Ryan está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD5.61M).
Compensación vs. Ingresos: La compensación de Ryan ha aumentado mientras la empresa no es rentable.
CEO
Ryan Spencer (45 yo)
4.4yrs
Permanencia
US$5,810,736
Compensación
Mr. Ryan Spencer serves as Director at Cidara Therapeutics, Inc. from April 24, 2024. He serves as Interim Chief Financial Officer of Dynavax Technologies Corporation since March 29, 2024. He serves as the...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO, Interim CFO & Director | 4.4yrs | US$5.81m | 0.18% $ 2.7m | |
| President & COO | 11.2yrs | US$2.99m | 0.024% $ 375.5k | |
| Chief Medical Officer and Senior VP of Clinical Development | 10.8yrs | US$1.88m | 0.049% $ 755.6k | |
| Senior VP & CFO (Leave of Absence) | less than a year | US$2.07m | 0.0059% $ 90.5k | |
| Chief Accounting Officer & Controller | 4yrs | sin datos | sin datos | |
| Senior VP & Chief Human Resources Officer | 5.3yrs | sin datos | sin datos | |
| VP of Investor Relations & Corporate Communications | 1.3yrs | sin datos | sin datos | |
| Senior VP & General Counsel | 2.9yrs | sin datos | sin datos | |
| Senior VP & Chief Commercial Officer | no data | sin datos | sin datos | |
| Senior Vice President of Vaccine Research | 3.3yrs | sin datos | sin datos | |
| VP, Site Head & MD for Dynavax GmbH | 3.3yrs | sin datos | sin datos | |
| Senior Vice President of Technical Operations | 3.3yrs | sin datos | sin datos |
3.3yrs
Permanencia media
58.5yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de DVAX se considera experimentado (3.3 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO, Interim CFO & Director | 4.4yrs | US$5.81m | 0.18% $ 2.7m | |
| Independent Director | 17.8yrs | US$298.73k | 0.021% $ 326.1k | |
| Independent Director | 13.8yrs | US$290.73k | 0.0011% $ 17.7k | |
| Independent Director | 14.5yrs | US$278.73k | 0.016% $ 245.0k | |
| Member of Scientific Advisory Board | 1.3yrs | US$1.83m | sin datos | |
| Member of Scientific Advisory Board | 5.9yrs | sin datos | sin datos | |
| Independent Director | 3.8yrs | US$293.73k | 0% $ 0 | |
| Member of Scientific Advisory Board | 5.9yrs | US$20.00k | sin datos | |
| Independent Chairman of the Board | 2.6yrs | US$323.73k | 0% $ 0 | |
| Member of Scientific Advisory Board | 5.9yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 5.9yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 5.9yrs | sin datos | sin datos |
5.9yrs
Permanencia media
72.5yo
Promedio de edad
Junta con experiencia: La junta directiva de DVAX se considera experimentada (5.8 años de antigüedad promedio).